Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:08:14.598Z.
Calculation as of: 2026-10-06T17:08:14.598Z.
Quote observation: 2026-10-06T17:05:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Odyssey Therapeutics, Inc.
Market Cap
$913.56M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.89M
Price/FCF Ratio
18.73
TTM Avg
13.52
3Y Avg
15.51
5Y Avg
16.87
Market Cap
$936.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885.42M
Price/FCF Ratio
N/A
TTM Avg
27.25
3Y Avg
19.97
5Y Avg
19.97
Market Cap
$942.14M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $913.56M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.89M | 18.73 | 13.52 | 15.51 | 16.87 |
| Bioventus Inc. (BVS)vs › | $897.63M | 9.52 | 9.57 | 34.87 | 48.37 |
| CeriBell, Inc. (CBLL)vs › | $932.29M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $936.20M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $885.42M | N/A | 27.25 | 19.97 | 19.97 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $942.14M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $949.44M | N/A | 6.84 | 6.83 | 6.83 |
| Savara Inc. (SVRA)vs › | $951.68M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $866.97M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
